AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32297054 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically guided TAP block with 10 ml of 0.25% bupivacaine at each of the four sites
Number of subjects: 100
Study 32297054 — intervention group
Group type: COMPARATOR
Intervention: Port site infiltration with 0.25% bupivacaine
Number of subjects: 100
Study 32297054 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically guided TAP block
Number of subjects: 100
Study 33876562 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise (150 min/week)
Number of subjects: 98
Study 33876562 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise (120 min/week)
Number of subjects: 98
Study 33876562 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular lifestyle)
Number of subjects: 98
Study 34339951 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 8 U/kg
Number of subjects: 350
Study 34339951 — intervention group
Group type: COMPARATOR
Intervention: IncobotulinumtoxinA 2 U/kg
Number of subjects: 350
Study 34339951 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 6 U/kg
Number of subjects: 350
Study 34339951 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (all doses)
Number of subjects: 350
Study 32321385 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week endurance training
Number of subjects: 52
Study 32321385 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week resistance training
Number of subjects: 52
Study 32321385 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 52
Study 35019975 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 1552
Study 33687487 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-119 75 μg
Number of subjects: 251
Study 33687487 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-119 150 μg
Number of subjects: 251
Study 33687487 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-119 200 μg
Number of subjects: 251
Study 33687487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 34802339 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 577
Study 34802339 — intervention group
Group type: COMPARATOR
Intervention: Community-based HIV testing services (HTS)
Number of subjects: 577
Study 34802339 — intervention group
Group type: COMPARATOR
Intervention: HTS
Number of subjects: 577
Study 34477813 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex ligand‐dependent probe amplification (MLPA)
Number of subjects: 498
Study 34477813 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 498
Study 34477813 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔIKZF1 alterations (including DN or loss‐of‐function lesions)
Number of subjects: 498
Study 34477813 — intervention group
Group type: EXPERIMENTAL
Intervention: IKZF1plus genotype
Number of subjects: 498
Study 35853272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative sublingual 400mcg misoprostol
Number of subjects: 0
Study 35853272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34387949 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise‐induced hypoalgesia
Number of subjects: 19
Study 34387949 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 19
Study 34387949 — intervention group
Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 19
Study 32353822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 60
Study 32353822 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 35704338 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes (0.4 mg/g nicotine)
Number of subjects: 286
Study 32669641 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printing
Number of subjects: 61
Study 32669641 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-image
Number of subjects: 61
Study 32669641 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study 32661291 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h Physical Activity Recall (24PAR)
Number of subjects: 1247
Study 32661291 — intervention group
Group type: EXPERIMENTAL
Intervention: SenseWear Armband (SWA)
Number of subjects: 1247
Study 32661291 — intervention group
Group type: COMPARATOR
Intervention: SWA vs 24PAR
Number of subjects: 1247
Study 32520577 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 195
Study 32520577 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion in LPS-challenged volunteers
Number of subjects: 195
Study 32520577 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher norepinephrine infusion rates in patients
Number of subjects: 195
Study 32520577 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use in patients
Number of subjects: 195
Study 32520577 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 195
Study 35575754 — intervention group
Group type: EXPERIMENTAL
Intervention: OpenPose
Number of subjects: 14
Study 35575754 — intervention group
Group type: EXPERIMENTAL
Intervention: MSRA
Number of subjects: 14
Study 33716112 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group (n=9)
Number of subjects: 17
Study 33716112 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 17
Study 32143737 — intervention group
Group type: EXPERIMENTAL
Intervention: Early continuous Kangaroo Mother Care (KMC) within 24 hours of admission
Number of subjects: 392
Study 32143737 — intervention group
Group type: COMPARATOR
Intervention: Standard care (incubator or radiant heater with KMC when clinically stable at > 24 hours of admission)
Number of subjects: 392
Study 35833783 — intervention group
Group type: EXPERIMENTAL
Intervention: napabucasin plus paclitaxel
Number of subjects: 714
Study 35833783 — intervention group
Group type: COMPARATOR
Intervention: placebo plus paclitaxel
Number of subjects: 714
Study 33263447 — intervention group
Group type: EXPERIMENTAL
Intervention: HXLPE/VitE acetabular cups
Number of subjects: 62
Study 33263447 — intervention group
Group type: COMPARATOR
Intervention: UHMWPE acetabular cups
Number of subjects: 62
Study 33263447 — intervention group
Group type: EXPERIMENTAL
Intervention: HXLPE/VitE and UHMWPE cups
Number of subjects: 62
Study 35838942 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (0.3 mg/kg for < 10 kg, 3 mg for 10-15 kg, 6 mg for > 15 kg)
Number of subjects: 228
Study 35838942 — intervention group
Group type: COMPARATOR
Intervention: Triclofos (50 mg/kg, max 1 g for 6 mo to 11 y; 2 g for 11 to 18 y)
Number of subjects: 228
Study 35838942 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 228
Study 35838942 — intervention group
Group type: COMPARATOR
Intervention: Triclofos
Number of subjects: 228
Study 34858912 — intervention group
Group type: EXPERIMENTAL
Intervention: CHE households
Number of subjects: 0
Study 36104714 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative echocardiography
Number of subjects: 4514
Study 36104714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative echocardiography)
Number of subjects: 4514
Study 34370612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmersive virtual reality (VR) intervention associated with conventional therapy
Number of subjects: 22
Study 34370612 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 22
Study 32898379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency Ablation (CRFA)
Number of subjects: 175
Study 32898379 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 175
Study 35351707 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual goal-based plan based on nursing theory
Number of subjects: 110
Study 36360667 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational program (yoga training)
Number of subjects: 33
Study 36360667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 32110003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Matters intervention
Number of subjects: 13
Study 35999816 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient engagement strategies including bi-weekly meetings, newsletters, and educational materials.
Number of subjects: 0
Study 35999816 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-driven initiative to draft letters sharing personal stories.
Number of subjects: 0
Study 35756427 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort care
Number of subjects: 118
Study 35756427 — intervention group
Group type: COMPARATOR
Intervention: WNNM algorithm
Number of subjects: 118
Study 32555011 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned feeding experience involving a tactile component (touch and/or holding) during feedings
Number of subjects: 120
Study 32555011 — intervention group
Group type: COMPARATOR
Intervention: Usual feeding care
Number of subjects: 120
Study 36306132 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g intravenous casirivimab and imdevimab
Number of subjects: 657
Study 36306132 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0 g intravenous casirivimab and imdevimab
Number of subjects: 657
Study 36306132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 657
Study 34519801 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (paclitaxel 175 mg/m2 and cisplatin 75 mg/m2)
Number of subjects: 596
Study 34519801 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (paclitaxel 175 mg/m2 and cisplatin 75 mg/m2)
Number of subjects: 596
Study 34519801 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 596
Study 34519801 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 596
Study 35527346 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-guided occult lesion localisation using iodine-125 (ROLLIS)
Number of subjects: 659
Study 33221561 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 138
Study 33221561 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 138
Study 35886524 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic hydroxyapatite toothpaste
Number of subjects: 40
Study 35886524 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste (1450 ppm)
Number of subjects: 40
Study 33783104 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check‐Up 4 Health (FCU4Health) program (N = 141)
Number of subjects: 240
Study 33783104 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus information (N = 99)
Number of subjects: 240
Study 32454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment
Number of subjects: 442
Study 32454794 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 442
Study 35973655 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut allergen powder‐dnfp (PTAH)
Number of subjects: 506
Study 35973655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 34510911 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch technique
Number of subjects: 2655
Study 34510911 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 2655
Study 35377447 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 150
Study 35377447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanraplenib 30 mg
Number of subjects: 150
Study 35377447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirabrutinib 40 mg
Number of subjects: 150
Study 35377447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 33986043 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour game jam (1-hour lecture + 4-hour game creation and play session)
Number of subjects: 79
Study 33986043 — intervention group
Group type: COMPARATOR
Intervention: 1-hour conventional lesson + 4-hour study session of selected readings
Number of subjects: 79
Study 35329211 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly content with customised behaviour change techniques (experimental group)
Number of subjects: 0
Study 35329211 — intervention group
Group type: COMPARATOR
Intervention: Single-time and non-customised delivery of food-related international guidelines (comparison group)
Number of subjects: 0
Study 33251659 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 35011103 — intervention group
Group type: EXPERIMENTAL
Intervention: Loigolactobacillus coryniformis K8 CECT 5711
Number of subjects: 200
Study 35011103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32667902 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline consumption (423 mL of normal saline, sodium 154 mmol/L)
Number of subjects: 24
Study 32667902 — intervention group
Group type: COMPARATOR
Intervention: Control (no saline consumption)
Number of subjects: 24
Study 33622669 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg TTP399
Number of subjects: 105
Study 33622669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 37458867 — intervention group
Group type: EXPERIMENTAL
Intervention: 3200 × 5
Number of subjects: 128
Study 37458867 — intervention group
Group type: EXPERIMENTAL
Intervention: 3200 × 10
Number of subjects: 128
Study 37458867 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 128
Study 33464300 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat 25 mg
Number of subjects: 557
Study 33464300 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat (5 mg and 25 mg)
Number of subjects: 557
Study 33464300 — intervention group
Group type: COMPARATOR
Intervention: Follow-up after stopping treatment
Number of subjects: 557
Study 33464300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study 32601653 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy program (18-week duration)
Number of subjects: 22
Study 35584268 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection with splint (40 mg methylprednisolone + 0.5 ml lidocaine, splint worn full time for 3 months)
Number of subjects: 60
Study 35584268 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection without splint (40 mg methylprednisolone + 0.5 ml lidocaine)
Number of subjects: 60
Study 34315722 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 60
Study 34315722 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 60
Study 35027324 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI-ox with FOLFOX + targeted therapy or FOLFOXIRI + bevacizumab
Number of subjects: 348
Study 35027324 — intervention group
Group type: COMPARATOR
Intervention: Systemic oxaliplatin with FOLFOX + targeted therapy or FOLFOXIRI + bevacizumab
Number of subjects: 348
Study 35027324 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI-ox
Number of subjects: 348
Study 35027324 — intervention group
Group type: COMPARATOR
Intervention: Systemic oxaliplatin
Number of subjects: 348
Study 34271948 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intensive therapy (MT)
Number of subjects: 395
Study 34271948 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SoC)
Number of subjects: 395
Study 35437101 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (8am-11am)
Number of subjects: 19
Study 35437101 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon exercise (5pm-8pm)
Number of subjects: 19
Study 35274344 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based oral exercises (tongue-strengthening, oral diadochokinesis, mouth-opening exercises) for 3 months
Number of subjects: 22
Study 35274344 — intervention group
Group type: COMPARATOR
Intervention: Advice on oral health care (Control group)
Number of subjects: 22
Study 34057643 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoids plus placebo (G3)
Number of subjects: 68
Study 34057643 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole plus flavonoids (G4)
Number of subjects: 68
Study 34057643 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole plus placebo (G2)
Number of subjects: 68
Study 34057643 — intervention group
Group type: COMPARATOR
Intervention: Double-placebo (G1)
Number of subjects: 68
Study 36191453 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 66
Study 36191453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 34769711 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation
Number of subjects: 20
Study 34769711 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation
Number of subjects: 20
Study 32513161 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVEdiabetes programme (PA consultations, pedometers, WhatsApp messages)
Number of subjects: 232
Study 34652335 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb resistance training (RT)
Number of subjects: 10
Study 34652335 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training (CT)
Number of subjects: 10
Study 34652335 — intervention group
Group type: COMPARATOR
Intervention: Intermittent sprint protocol (ISP)
Number of subjects: 10
Study 34652335 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise conditions
Number of subjects: 10
Study 34652335 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 10
Study 34936272 — intervention group
Group type: EXPERIMENTAL
Intervention: Wangbuliuxing decoction (oral administration, twice a day for 7 days) combined with massage at breast and acupoint (Zhongfu [LU 1], Yunmen [LU 2], Danzhong [CV 17], 2 min per acupoint, twice a day for 7 days)
Number of subjects: 120
Study 34936272 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 120
Study 36435917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless deep sclerectomy
Number of subjects: 50
Study 36435917 — intervention group
Group type: COMPARATOR
Intervention: Conventional deep sclerectomy
Number of subjects: 50
Study 36435917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 32694376 — intervention group
Group type: EXPERIMENTAL
Intervention: HVREX (exercise hypoxic ventilatory response)
Number of subjects: 16
Study 32694376 — intervention group
Group type: EXPERIMENTAL
Intervention: HVRREST (rest hypoxic ventilatory response)
Number of subjects: 16
Study 32694376 — intervention group
Group type: COMPARATOR
Intervention: 10-km cycling TT in hypoxic gas mixture (FiO2 = 0.16)
Number of subjects: 16
Study 32694376 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-km cycling TT in room air (FiO2 = 0.21)
Number of subjects: 16
Study 32191129 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing sample size or replacing subjects who drop out
Number of subjects: 0
Study 32191129 — intervention group
Group type: EXPERIMENTAL
Intervention: Attrition of subjects in a cohort design
Number of subjects: 0
Study 32191129 — intervention group
Group type: EXPERIMENTAL
Intervention: Attrition of clusters
Number of subjects: 0
Study 35459233 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 29
Study 35315622 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 80
Study 35315622 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate infusion
Number of subjects: 80
Study 33586143 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (maintenance dose = 1,200 mg/2 weeks)
Number of subjects: 137
Study 33586143 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 137
Study 33586143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from PREVENT)
Number of subjects: 137
Study 32483161 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 496
Study 32483161 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 496
Study 32483161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 496
Study 34470506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 102
Study 35002228 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC
Number of subjects: 20
Study 35002228 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infusion of BMMC and ADSC
Number of subjects: 20
Study 35002228 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 20
Study 35724559 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (tVNS)
Number of subjects: 30
Study 35724559 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 32660542 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (24 μg/kg) for four or six monthly doses
Number of subjects: 6
Study 32660542 — intervention group
Group type: COMPARATOR
Intervention: Heartgard® Plus (ivermectin/pyrantel) for six monthly doses
Number of subjects: 6
Study 32660542 — intervention group
Group type: COMPARATOR
Intervention: Interceptor® Plus (milbemycin oxime/praziquantel) for six monthly doses
Number of subjects: 6
Study 36400376 — intervention group
Group type: EXPERIMENTAL
Intervention: EC skin test (ECST)
Number of subjects: 1085
Study 36400376 — intervention group
Group type: COMPARATOR
Intervention: TST (tuberculin skin test)
Number of subjects: 1085
Study 36400376 — intervention group
Group type: COMPARATOR
Intervention: T-SPOT.TB
Number of subjects: 1085
Study 33180306 — intervention group
Group type: EXPERIMENTAL
Intervention: One-level RDL reductions achieved by 84% of patients at the end of treatment; 84.9% maintained reduction at 3-year follow-up.
Number of subjects: 1500
Study 33180306 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level RDL reductions achieved by 68% of patients at the end of treatment; 77.7% maintained reduction at 3-year follow-up.
Number of subjects: 1500